Benitec Biopharma Inc. — Form 8-K
Filed October 28, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Benitec announced positive interim results from its BB-301 first-in-human Phase 1b/2a study in oculopharyngeal muscular dystrophy (OPMD). All 9 patients treated (6 low-dose Cohort 1, 3 high-dose Cohort 2) achieved formal responder status for swallowing function improvements, with high-dose cohort showing greater improvements in throat emptying and swallowing capacity at 3-month follow-up (100% vs 67% low-dose for throat emptying; 67% vs 17% for functional capacity). No serious adverse events reported; pivotal study planned for mid-2027.
Why this rating
Early-stage biotech with $153M market cap; positive Phase 1b/2a data on lead asset addresses orphan disease with no approved therapies (15k patients). 100% response rate is encouraging but small N=9 sample. Pivotal study upcoming; significant milestone risk/reward ahead.
Tradability signal
NO TRADE
No trade: positive news with only -1.3% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.48% over 4 hrs, n=250). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $8.58 | +10 min · unknown $8.19 ▼ 4.55% | +30 min · unknown $8.71 ▲ 1.46% | +1 hr · unknown $8.68 ▲ 1.11% | +4 hrs · unknown $8.73 ▲ 1.75% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.